Agreed, NMUS trades at a fraction of the value of CBIS, IN.to, MJNA, and LXRP....all of which are also pre-clinical, pre-revenue companies with debatable drug candidates and credibility in pharmaceutical development experience. I don't see any good reason why Nemus trades at less than half the average valuation of the aforementioned companies. On a relative valuation basis, I think it deserves to be valued above the average of those other companies valuations....being affiliated with the only US approved research agency has to be worth something more.
I also agree there should be more news coming on the pipeline update, capital restructuring, and plan to uplist.
News 
Market Data 
Discover 
AI
